Cost-Related Medication Nonadherence and Patient Cost Responsibility for Rural and Urban Cancer Survivors
- 1 August 2022
- journal article
- conference paper
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 18 (8) , e1234-e1246
Abstract
The relationship between out-of-pocket spending and cost-related medication nonadherence among older rural- and urban-dwelling cancer survivors is not well understood. This retrospective cohort study used the Surveillance, Epidemiology, and End Results Program, Medicare claims, and the Consumer Assessment of Healthcare Providers and Systems survey linked data resource linked data (2007-2015) to investigate the relationship between cancer survivors' cost responsibility in the year before and after report of delaying or not filling a prescription medication because of cost in the past 6 months (cost-related medication nonadherence). Secondary exposures and outcomes included Medicare spending and utilization. Generalized linear models assessed bidirectional relationships between cost-related medication nonadherence, spending, and utilization. Effects of residence were assessed via interaction terms. Of 6,591 older cancer survivors, 13% reported cost-related medication nonadherence. Survivors were a median 8 years (interquartile range, 4.5-12.5 years) from their cancer diagnosis, 15% were dually Medicare/Medicaid-eligible, and prostate (40%) and breast (32%) cancer survivors were most prevalent. With every $500 USD increase in patient cost responsibility, risk of cost-related medication nonadherence increased by 3% (risk ratio, 1.03; 95% CI, 1.02 to 1.04). After report of cost-related medication nonadherence, patient cost responsibility was 22% higher (95% CI, 1.11 to 1.32) compared with those not reporting nonadherence, amounting to $523 USD (95% CI, $430 USD to $630 USD). Medicare spending and utilization were also higher before and after report of cost-related nonadherence versus none. For survivors residing in rural (18%) and urban (82%) areas, residence did not modify adherence or cost outcomes. A bidirectional relationship exists between patient cost responsibility and cost-related medication nonadherence. Interventions reducing urban- and rural-dwelling survivor health care costs and cost-related adherence barriers are needed.Keywords
This publication has 52 references indexed in Scilit:
- Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid LeukemiaJournal of Clinical Oncology, 2014
- Economic Burden of Cancer Survivorship Among Adults in the United StatesJournal of Clinical Oncology, 2013
- Impact of Rural Residence on Forgoing Healthcare after Cancer Because of CostCancer Epidemiology, Biomarkers & Prevention, 2013
- Hunger and Socioeconomic Disparities in Chronic DiseaseNew England Journal of Medicine, 2010
- Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancerBreast Cancer Research and Treatment, 2010
- Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patientsCurrent Medical Research and Opinion, 2009
- Treatment Interruptions and Non-Adherence with Imatinib and Associated Healthcare CostsPharmacoEconomics, 2007
- Adapting a clinical comorbidity index for use with ICD-9-CM administrative databasesJournal of Clinical Epidemiology, 1992
- A power primer.Psychological Bulletin, 1992
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987